Eli Lilly has shared positive two-year results from an open-label extension (OLE) study of Omvoh (mirikizumab-mrkz) in active ...

"Eli Lilly reports positive data from trial of Omvoh for Crohn’s disease" was originally created and published by Clinical ...

INDIANAPOLIS—Lilly Endowment Inc., a major shareholder in Eli Lilly & Co. (NYSE:LLY), has recently sold a significant portion ...

Eli Lilly has announced results from the VIVID-2 open-label extension study, showing that most patients with moderately to ...

Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress: Indianapolis Monday, February 10, 20 ...

Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

These growth stocks come from two very different industries. Eli Lilly is riding the GLP-1 drug wave, but there is much more ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn ...

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Company ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...